ZYMERGEN INC. [●] Shares of Common Stock Underwriting AgreementUnderwriting Agreement • April 14th, 2021 • Zymergen Inc. • Services-commercial physical & biological research • New York
Zymergen Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom J.P. Morgan Securities LLC and Goldman Sachs & Co. LLC are acting as representatives (the “Representatives”), an aggregate of [●] shares of Common Stock, par value $[●] per share, of the Company (the “Underwritten Shares”) and, at the option of the Underwriters, up to an additional [●] shares of Common Stock of the Company (the “Option Shares”). The Underwritten Shares and the Option Shares are herein referred to as the “Shares”. The shares of Common Stock of the Company to be outstanding after giving effect to the sale of the Shares are referred to herein as the “Stock”.
ZYMERGEN INC. INDEMNIFICATION AGREEMENTIndemnification Agreement • April 14th, 2021 • Zymergen Inc. • Services-commercial physical & biological research • Delaware
This Indemnification Agreement (this “Agreement”) is made as of, April __, 2021 by and between Zymergen Inc., a Delaware corporation (the “Company”), and a member of the Board of Directors or an officer of the Company (“Indemnitee”).
